Daiichi Sankyo Company (DSKYF) Fair Value & Analysis
Healthcare · US · Market cap $30.2B
Daiichi Sankyo Company
DSKYF · US
Fair value as of: Jun 24, 2026
From 17 valuation models · updated 7 days ago
Share price −7.9% over the past month.
Price vs Fair Value (12 months)
12‑month range $14.59 – $28.15 · fair‑value band $6.06 – $18.03 · the $15.52 price screens above the $8.41 fair value. As of Jun 24, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Daiichi Sankyo Company (DSKYF) currently trades at $15.52, while our model-based Fair Value estimate is $8.41 — implying the stock looks roughly 45.8% overvalued today. We read business quality at 43/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
Over the trailing twelve months, Daiichi Sankyo Company generated revenue of $2.1T at a net margin of 12.2%. Revenue grew 13.7% year over year. It earns a return on equity of 15.8%. The balance sheet holds a net cash position of $150B. Fundamentals as of Jun 24, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 24, 2026. TTM = trailing twelve months.
About the company
Daiichi Sankyo Company, Limited manufactures and sells pharmaceutical products in Japan, the United States, Europe, and internationally. The company offers Enhertu to treat patients with HER2 positive and low breast cancer, HER2 positive gastric or gastroesophageal junction adenocarcinoma, and HER2 positive solid tumors; Turalio, an oral small molecule that targets colony stimulating factor 1 receptor, KIT proto-oncogene receptor tyrosine kinase, and FMS-like tyrosine kinase 3 harboring an internal tandem duplication mutation for the treatment of symptomatic TGCT; Vanflyta, a FLT3 inhibitor to treat patients with acute myeloid leukemia; Injectafer, a ferric carboxymaltose injection for the treatment of iron deficiency; and DATROWAY to treat adult patients with breast cancer and NSCLC. It also provides Liziana and Savaysa, which are direct factor Xa inhibitors; Minnebro, Olmetec, Olmetec Plus, Rezaltas, Sevikar, and Sevikar HCT, which are antihypertensive agents; Nilemdo, an oral …
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
Daiichi Sankyo Company reported revenue of $2.1T in FY2026 versus $1.0T in FY2022, a compound +19.6%/yr. Reported net income was $262B in FY2026, compounding +40.6%/yr from FY2022.
Is DSKYF fairly valued? → Check now
Recent news
- AstraZeneca's Enhertu Wins EU Nod for HER2-Positive Solid Tumors
- Enhertu® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated H
- Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who
- OpenFold Consortium Adds Eleven New Members as Momentum Builds for Open AI Infrastructure in Biology and Drug Discovery
External third-party headlines (Yahoo Finance, Reuters and others) — not an editorial selection, not financial advice.
Similar stocks
6 more Drug Manufacturers - General stocks, each showing price versus our Fair Value estimate (as of Jun 24, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Eli Lilly and Company LLY | $1,136 | $630.79 | -44% |
| Johnson & Johnson, JNJ | 4,128 MXN | 2,401 MXN | -42% |
| AbbVie Inc ABBV | $230.01 | $133.86 | -42% |
| Roche Holding ROGN | 7,050 MXN | 316.37 MXN | -96% |
| Merck & Co MRK | $120.79 | $66.05 | -45% |
| AstraZeneca PLC A1ZN34 | R$159.89 | R$87.02 | -46% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Daiichi Sankyo Company (DSKYF) undervalued?
What is the fair value of DSKYF?
What is the quality score of DSKYF?
What is the revenue of Daiichi Sankyo Company (DSKYF)?
What is the net profit margin of DSKYF?
Does Daiichi Sankyo Company pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.